← All trials
NCT05794425
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2023
- Primary completion
- Apr 30, 2025
- Completion date
- Apr 30, 2026
- First posted
- Apr 3, 2023
- Last posted
- Nov 29, 2023
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Qilu Pharmaceutical Co., Ltd.Lead sponsor
- Binzhou Medical UniversityCollaborator
- Dezhou People's Hospital,ShandongCollaborator
- Tumor Hospital of GansuCollaborator
- Jiangxi Children's HospitalCollaborator
- Jining NO.1 People 's HospitalCollaborator
- Kaifeng Central HospitalCollaborator
- Yishui Central Hospital of LINYICollaborator
- Linyi People's HospitalCollaborator
- People's Hospital of RizhaoCollaborator
- Zhengzhou UniversityCollaborator
- Shandong Provincial Third HospitalCollaborator
- Shandong Provincial Third HospitalOverall official - principal investigator
- Shandong University of Traditional Chinese MedicineCollaborator
- The First People's Hospital of JingzhouCollaborator
- Harbin Medical UniversityCollaborator
- Shandong first medical UniversityCollaborator
- Shandong UniversityCollaborator
- Weihai Central HospitalCollaborator
- Weihai Municipal HospitalCollaborator
- Zhengzhou UniversityCollaborator
- Zibo City First HospitalCollaborator
- Shengli Oilfield Central HospitalCollaborator
- Tai'an Central HospitalCollaborator
- Shandong Provincial Third HospitalOfficial
- Government of ChinaOfficial
- Nanjing Medical UniversityCollaborator
- Government of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.